BKT140
产品编号: DC10423
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Motixafortide (BKT140 4-fluorobenzoyl) 是一种新型的CXCR4拮抗剂，IC50约为1 nM。
| Cas No.: |
664334-36-5 |
| 名称: |
|
| 别名: |
BL-8040; TF14016; 4F-Benzoyl-TN14003 |
| SMILES: |
O=C1[C@@]2([H])N(CCC2)C([C@@](NC([C@@H](NC([C@](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(C3=CC=C(F)C=C3)=O)=O)=O)CC4=CC5=C(C=CC=C5)C=C4)=O)CSSC[C@](C(N[C@H](C(N)=O)CCCNC(N)=N)=O)([H])NC([C@H](CCCNC(N)=O)NC([C@@](CCCNC(N)=N) |
| 分子式: |
C97H144FN33O19S2 |
| 分子量: |
2159.52 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
BKT140 displays selective toxicity toward AmL and MM cells. Treatment with BKT140 can overcome IL-6 dependent proliferation and survival of ARH77 MM cells. BKT140 specifically triggers CXCR4-dependent cell death in leukemia and MM cells. BKT140 stimulates apoptotic cell death in leukemia and MM cells.Subcutaneous injections of BKT140 significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. Tumors from animals treated with BKT140 are smaller in size and weights, had larger necrotic areas and high apoptotic scores. |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
